The Prognostic Value of Whole Blood SOX2, NANOG and OCT4 MRNA Expression in Advanced Small-cell Lung Cancer

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2016 Jun 2

PMID 27247551

Citations 23

Authors

Eva Sodja

Matija Rijavec

Ana Koren

Aleksander Sadikov

Peter Korosec

Tanja Cufer

Affiliations

Soon will be listed here.

Abstract

Background: The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy controls, and to correlate mRNA expression with progression-free survival (PFS) after first-line chemotherapy and overall survival (OS) in advanced SCLC patients.

Patients And Methods: 50 advanced SCLC patients treated with standard chemotherapy and followed at University Clinic Golnik, Slovenia, between 2009 and 2013 were prospectively included. SOX2, NANOG and OCT4 mRNA expression levels were determined using TaqMan qPCR in whole blood collected prior to chemotherapy. Whole blood of 34 matched healthy individuals with no cancerous disease was also tested.

Results: SOX2 mRNA expression was significantly higher in whole blood of SCLC patients compared to healthy controls (p = 0.006). Significant correlation between SOX2 mRNA expression levels and the number of distant metastatic sites was established (p = 0.027). In survival analysis, patients with high SOX2 expression had shorter OS (p = 0.017) and PFS (p = 0.046). In multivariate Cox analysis, an independent value of high SOX2 expression for shorter OS (p = 0.002), but not PFS was confirmed. No significant differences were observed for NANOG or OCT4 expression levels when comparing SCLC patients and healthy controls neither when analysing survival outcomes in SCLC patients.

Conclusions: SOX2 mRNA expression in whole blood might be a promising non-invasive marker for molecular screening of SCLC and important prognostic marker in advanced chemotherapy-treated SCLC patients, altogether indicating important role of cancer stem-like cell (CSC) regulators in cancer spread. Further evaluation of SOX2 as a possible screening/prognostic marker and a therapeutic target of SCLC is warranted.

Citing Articles

Pershina O, Ermakova N, Pakhomova A, Pan E, Sandrikina L, Zhukova M Bull Exp Biol Med. 2024; 176(4):486-490.

PMID: 38492106 DOI: 10.1007/s10517-024-06052-9.

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells via β-Catenin Proteasomal Degradation in Human Lung Cancer.

Ei Z, Racha S, Yokoya M, Hotta D, Zou H, Chanvorachote P Mar Drugs. 2023; 21(12).

PMID: 38132948 PMC: 10744608. DOI: 10.3390/md21120627.

Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer.

Derderian S, Vesval Q, Wissing M, Hamel L, Cote N, Vanhuyse M Clin Transl Sci. 2022; 15(11):2597-2612.

PMID: 36172886 PMC: 9652435. DOI: 10.1111/cts.13372.

Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer.

Skurikhin E, Ermakova N, Zhukova M, Pershina O, Pan E, Pakhomova A Int J Mol Sci. 2022; 23(18).

PMID: 36142766 PMC: 9503899. DOI: 10.3390/ijms231810853.

Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set.

Hagmann R, Zippelius A, Rothschild S Cancers (Basel). 2022; 14(11).

PMID: 35681605 PMC: 9179878. DOI: 10.3390/cancers14112625.

References

Toschi L, Finocchiaro G, Nguyen T, Skokan M, Giordano L, Gianoncelli L . Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PLoS One. 2014; 9(4):e95303. PMC: 3988173. DOI: 10.1371/journal.pone.0095303. View

Sullivan J, Minna J, Shay J . Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev. 2010; 29(1):61-72. PMC: 2864581. DOI: 10.1007/s10555-010-9216-5. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J . Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol. 2013; 6(12):2846-54. PMC: 3843264. View

Chiou S, Wang M, Chou Y, Chen C, Hong C, Hsieh W . Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010; 70(24):10433-44. DOI: 10.1158/0008-5472.CAN-10-2638. View

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

Pine S, Marshall B, Varticovski L . Lung cancer stem cells. Dis Markers. 2008; 24(4-5):257-66. PMC: 3850541. DOI: 10.1155/2008/396281. View

10.

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

11.

Jones P, Baylin S . The epigenomics of cancer. Cell. 2007; 128(4):683-92. PMC: 3894624. DOI: 10.1016/j.cell.2007.01.029. View

12.

Bhattacharjee A, Richards W, Staunton J, Li C, Monti S, Vasa P . Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98(24):13790-5. PMC: 61120. DOI: 10.1073/pnas.191502998. View

13.

Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H . Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res. 2012; 318(15):1799-807. DOI: 10.1016/j.yexcr.2012.04.011. View

14.

Tian Y, Jia X, Wang S, Li Y, Zhao P, Cai D . SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness. J Cancer Res Clin Oncol. 2014; 140(7):1117-24. DOI: 10.1007/s00432-014-1660-0. View

15.

Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y . Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol. 2011; 223(5):672-82. DOI: 10.1002/path.2827. View

16.

Lu Y, Futtner C, Rock J, Xu X, Whitworth W, Hogan B . Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010; 5(6):e11022. PMC: 2883553. DOI: 10.1371/journal.pone.0011022. View

17.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L . Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009; 106(38):16281-6. PMC: 2741477. DOI: 10.1073/pnas.0905653106. View

18.

Fujimura T, Takahashi S, Urano T, Takayama K, Sugihara T, Obinata D . Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer. Clin Cancer Res. 2014; 20(17):4625-35. DOI: 10.1158/1078-0432.CCR-13-1105. View

19.

Berns A . Stem cells for lung cancer?. Cell. 2005; 121(6):811-3. DOI: 10.1016/j.cell.2005.06.004. View

20.

Li X, Jia L, Shi M, Li X, Li Z, Li H . Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression. J Transl Med. 2013; 11:232. PMC: 3849263. DOI: 10.1186/1479-5876-11-232. View